

Fundamental dimension Equity attribute | AVAIPeer $0.09▼-10.80% Cap $13.85MP/E -7.1x QuantScore18/100 | ALIFLeader $0.00010.00% Cap $7.94KP/E 0.0x QuantScore56/100 | BQSTPeer $0.250.00% Cap $7.47MP/E -8.7x QuantScore36/100 |
|---|---|---|---|
1. QuantScore pillars0–100 per pillar · click a ticker for the factor breakdown | |||
Technical | |||
18/100 |
53/100 |
64/100 |
Valuation Multiples, PEG & DCF upside | 33/100 | 50/100 | 0/100 |
Health Piotroski, Altman Z, leverage & liquidity | 20/100 | 53/100 | 27/100 |
Growth Revenue / earnings growth & margins | 0/100 | 69/100 | 55/100 |
Sentiment Analyst ratings, targets & revisions | — | — | — |
2. Valuation multiples & capital pricingGreen highlight = best-in-class (lowest positive multiple) |
Trailing P/E | -7.1x | 0.0x | -8.7x |
Forward P/E (next FY) | — | — | — |
EV / EBITDA (TTM) | -11.0x | -0.0x | -13.2x |
Price / Sales | — | 0.0x | 40.5x |
Price / Free Cash Flow | -11.7x | -0.0x | -26.6x |
PEG ratio | 0.10 | -0.00 | -0.39 |
3. Financial health & solvencyLatest filings |
Piotroski F-Score | 2 / 9 | 1 / 9 | 4 / 9 |
Altman Z-Score | -21.30 (Distress) | -0.28 (Distress) | -5464.29 (Distress) |
Total debt / equity | -0.71 | 0.04 | -0.35 |
Quick ratio | 0.0x | 1.9x | 0.0x |
Interest coverage | -13.2x | 90.3x | -9.1x |
4. Growth & margins trajectoryLatest fiscal year |
Revenue growth YoY | — | +29.3% | +23.7% |
Net income growth YoY | -53.2% | -27.4% | -15.8% |
Gross margin (TTM) | 0.0% | 70.9% | 113.0% |
Operating margin (FY) | — | 17.4% | -469.3% |
FCF margin (FY) | — | -17.0% | -168.2% |
5. Trailing price performancePrice change over period |
1M return | -29.1% | +0.0% | +273.1% |
3M return | -46.7% | +0.0% | +278.8% |
6M return | -71.0% | +0.0% | +267.6% |
Year to date | -75.7% | +0.0% | -51.1% |
1Y return | -79.7% | +0.0% | -75.0% |
3Y return | -90.4% | 0.0% | +1001.3% |
6. DCF valuation & street consensusDCF model · analyst consensus |
DCF model fair value | $-0.0229 -125.5% premium | $-67.29 -67294139.4% premium | $-0.0063 -102.5% premium |
Wall Street consensus target | — — | — — | — — |
Consensus stance | — | — | — |